Treatment of autoimmune diseases

Details for Australian Patent Application No. 2010224355 (hide)

Owner Novartis AG

Inventors Nuesslein-Hildesheim, Barbara; Cooke, Nigel Graham; Albert, Rainer; Weiler, Sven

Agent Davies Collison Cave

Pub. Number AU-B-2010224355

Parent 2006289100

Filing date 21 September 2010

Wipo publication date 14 October 2010

Acceptance publication date 29 March 2012

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/02 (2006.01) Drugs for disorders of the nervous system

A61P 27/02 (2006.01) Drugs for disorders of the senses

Event Publications

7 October 2010 Complete Application Filed

14 October 2010 Application Open to Public Inspection

  Published as AU-B-2010224355

29 March 2012 Application Accepted

  Published as AU-B-2010224355

26 July 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010224356-Compositions containing flourine substituted olefins

2010224354-Cultivating seaweed